Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

Tesla's new car sales in Britain rose year-on-year in June amid a broader recovery in the electric-vehicle market, data ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

UK vehicle production continues to face constraints, with figures from the Society of Motor Manufacturers and Traders (SMMT) ...

The new car market recorded its second consecutive month of growth in June, with registrations rising 6.7% year-on-year ...